| 000 | nab a22 7a 4500 | ||
|---|---|---|---|
| 999 |
_c17096 _d17096 |
||
| 003 | PC17096 | ||
| 005 | 20221128114634.0 | ||
| 008 | 221128b xxu||||| |||| 00| 0 eng d | ||
| 040 | _cH12O | ||
| 041 | _aeng | ||
| 100 |
_91223 _aOrtiz Romero, Pablo Luis _eDermatología Médico-Quirúrgica y Venereología |
||
| 245 | 0 | 0 |
_aIndividualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. _h[artículo] |
| 260 |
_bOncotarget, _c2015 |
||
| 300 | _a6(28):25452-65. | ||
| 500 | _aFormato Vancouver: Curiel Olmo S, García Castaño A, Vidal R, Pisonero H, Varela I, León Castillo A et al. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. Oncotarget. 2015 Sep 22;6(28):25452-65. | ||
| 501 | _aPMID: 26327537 PMC4694844. | ||
| 504 | _aContiene 42 referencias | ||
| 505 | _aErratum in: Oncotarget. 2016 Feb 2;7(5):6352. | ||
| 520 | _aTargeted treatment of advanced melanoma could benefit from the precise molecular characterization of melanoma samples. Using a melanoma-specific selection of 217 genes, we performed targeted deep sequencing of a series of biopsies, from advanced melanoma cases, with a Breslow index of ≥ 4 mm, and/or with a loco-regional infiltration in lymph nodes or presenting distant metastasis, as well of a collection of human cell lines. This approach detected 3-4 mutations per case, constituting unique mutational signatures associated with specific inhibitor sensitivity. Functionally, case-specific combinations of inhibitors that simultaneously targeted MAPK-dependent and MAPK-independent mechanisms were most effective at inhibiting melanoma growth, against each specific mutational background. These observations were challenged by characterizing a freshly resected biopsy from a metastatic lesion located in the skin and soft tissue and by testing its associated therapy ex vivo and in vivo using melanocytes and patient-derived xenografted mice, respectively. The results show that upon mutational characterization of advanced melanoma patients, specific mutational profiles can be used for selecting drugs that simultaneously target several deregulated genes/pathways involved in tumor generation or progression. | ||
| 710 |
_9145 _aServicio de Dermatología Médico-Quirúrgica y Venereología |
||
| 710 |
_9625 _aInstituto de Investigación imas12 |
||
| 856 |
_uhttps://pubmed.ncbi.nlm.nih.gov/26327537/ _yAcceso libre |
||
| 942 |
_2ddc _cART _n0 |
||